Galmed Pharmaceuticals Ltd. (GLMD) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
GLMD EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GLMD Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export GLMD earnings history in CSV or JSON format
Free sign-in required to download data
Galmed Pharmaceuticals Ltd. (GLMD) Earnings Overview
As of May 8, 2026, Galmed Pharmaceuticals Ltd. (GLMD) reported trailing twelve-month net income of -$9M, reflecting +73.0% year-over-year growth. The company earned $-2.21 per diluted share over the past four quarters.
Looking at the long-term picture, GLMD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2012.
Galmed Pharmaceuticals Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$309M net income, -30.1% margin), AKBA (-$21M net income, -2.3% margin), HALO ($317M net income, 22.7% margin), GLMD has comparable earnings metrics. Compare GLMD vs MDGL →
GLMD Earnings vs Peers
Earnings metrics vs comparable public companies
GLMD Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$8M | -8.8% | -$6M | $-8.08 | - | - |
| 2023 | -$7M | +62.8% | $7M | $-29.95 | - | - |
| 2022 | -$19M | +41.9% | -$18M | $-11.08 | - | - |
| 2021 | -$32M | -15.7% | -$33M | $-19.48 | - | - |
| 2020 | -$28M | -48.9% | -$30M | $-19.46 | - | - |
| 2019 | -$19M | -88.1% | -$22M | $-13.17 | - | - |
| 2018 | -$10M | +19.9% | -$11M | $-8.15 | -483.6% | -525.8% |
| 2017 | -$12M | +27.5% | -$12M | $-14.77 | -1133.5% | -1139.5% |
| 2016 | -$17M | -59.6% | -$17M | $-22.36 | -3630.2% | -3615.0% |
| 2015 | -$11M | -16.7% | -$11M | $-14.35 | - | - |
See GLMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GLMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GLMD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGLMD — Frequently Asked Questions
Quick answers to the most common questions about buying GLMD stock.
Is GLMD growing earnings?
GLMD EPS is $-2.21, with earnings growth accelerating to +73.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are GLMD's profit margins?
Galmed Pharmaceuticals Ltd. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are GLMD's earnings?
GLMD earnings data spans 2012-2024. The accelerating earnings trend is +73.0% YoY. Historical data enables comparison across business cycles.